Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · bioAffinity Technologies, Inc. (BIAF)

bioAffinity to present sputum-based lung inflammation test data at CHEST 2026

Neutral Impact 1 of 5 product/contract Written later

bioAffinity Technologies announced it will present new research on investigational sputum-based tests that measure lung inflammation and protein biomarkers, including targets of asthma and COPD biologic drugs, at the CHEST 2026 meeting. The tests are not validated, not cleared or approved by the FDA, and not available for clinical or diagnostic use, so the update is a research milestone rather than a financial or commercial event.

Key points

  • Poster titled "Sputum as a Diagnostic Tool for the Measurement of Lung Inflammation in Asthma" is scheduled for October 20, 2026, 1:45-2:30 p.m. at the Phoenix Convention Center.
  • Chief Medical Officer Gordon Downie will lead a discussion at CHEST 2026 on October 21 at 12:30 p.m. in Learning Theater 4.
  • The tests are investigational, not validated, not FDA cleared or approved, and not currently available for clinical or diagnostic use.
  • The filing states no financial results, revenue or guidance figures.

The filing

CompanybioAffinity Technologies, Inc. (BIAF)
Form8-K, current report
Filed with the SECOct 13, 2026, 9:23 AM ET
Accession number0001493152-26-046755

Items reported: 8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 13, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.